%D8%AD%D8%B1%D9%83%D9%8A%D8%A9_%D8%AF%D9%88%D8%A7%D8%A6%D9%8A%D8%A9Farmacocin%C3%A9tica%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D0%BA%D0%BE%D0%BA%D0%B8%D0%BD%D0%B5%D1%82%D0%B8%D0%BA%D0%B0%E0%A6%94%E0%A6%B7%E0%A6%A7%E0%A6%B8%E0%A6%9E%E0%A7%8D%E0%A6%9A%E0%A6%B0%E0%A6%A3%E0%A6%AC%E0%A6%BF%E0%A6%9C%E0%A7%8D%E0%A6%9E%E0%A6%BE%E0%A6%A8Farmacocin%C3%A8ticaFarmakokinetikaFarmakokinetikPharmakokinetik%CE%A6%CE%B1%CF%81%CE%BC%CE%B1%CE%BA%CE%BF%CE%BA%CE%B9%CE%BD%CE%B7%CF%84%CE%B9%CE%BA%CE%AEPharmacokineticsFarmacocin%C3%A9ticaFarmakokineetika%D9%81%D8%A7%D8%B1%D9%85%D8%A7%DA%A9%D9%88%DA%A9%DB%8C%D9%86%D8%AA%DB%8C%DA%A9FarmakokinetiikkaPharmacocin%C3%A9tiqueFarmacocin%C3%A9tica%D7%A4%D7%A8%D7%9E%D7%A7%D7%95%D7%A7%D7%99%D7%A0%D7%98%D7%99%D7%A7%D7%94FarmakokinetikaFarmakokinetikaFarmacocinetica%E8%96%AC%E7%89%A9%E5%8B%95%E6%85%8B%E5%AD%A6%EC%95%BD%EB%AC%BC%EB%8F%99%ED%83%9C%ED%95%99%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D0%BA%D0%BE%D0%BA%D0%B8%D0%BD%D0%B5%D1%82%D0%B8%D0%BA%D0%B0PharmacocineticaFarmacoqinetegaFarmakokinetikaFarmakokin%C4%93tika%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D0%BA%D0%BE%D0%BA%D0%B8%D0%BD%D0%B5%D1%82%D0%B8%D0%BA%D0%B0%E0%A4%AB%E0%A4%BE%E0%A4%B0%E0%A5%8D%E0%A4%AE%E0%A4%BE%E0%A4%95%E0%A5%8B%E0%A4%95%E0%A4%BE%E0%A4%AF%E0%A4%A8%E0%A5%87%E0%A4%9F%E0%A4%BF%E0%A4%95%E0%A5%8D%E0%A4%B8FarmacokinetiekFarmakokinetikkFarmakokinetykaFarmacocin%C3%A9ticaFarmacocinetic%C4%83%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D0%BA%D0%BE%D0%BA%D0%B8%D0%BD%D0%B5%D1%82%D0%B8%D0%BA%D0%B0PharmacokineticsFarmakokinetikaPharmacokineticsFarmakokinetikaFarmakokinetika
about
sameAs
P800
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administrationAssessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malariaPharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studiesSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesChemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailabilityPharmacokinetic Comparison of Isoalantolactone and Alantolactone in Rats after Administration Separately by Optimization of an UPLC-MS 2 MethodUpdate on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part I: Program Implementation and Lessons LearnedNew Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus MefloquineEffect of Cephalexin on the Pharmacokinetics of Metformin in Healthy Human VolunteersClinical Pharmacokinetics of MetforminPharmacokinetics and Clinical Effectiveness of MethylphenidateAmphetamine-Type Medicines: A Review of Pharmacokinetics, Pharmacodynamics, and Toxicological AspectsUse of Benzodiazepines during Pregnancy, Labour and Lactation, with Particular Reference to Pharmacokinetic ConsiderationsPharmacokinetic Drug Interactions with Oral ContraceptivesPharmacokinetic Determinants of Drug Abuse and DependenceAn introduction to the use of physiologically based pharmacokinetic models in risk assessmentApplication of an updated physiologically-based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and miceComparative pharmacokinetics of chlorpyrifos versus its major metabolites following oral administration in the ratAssessment of health effects of fluctuating concentrations using simplified pharmacokinetic algorithmsPhysiologically based pharmacokinetic modeling for 1-bromopropane in F344 rats using gas uptake inhalation experimentsDevelopment of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the ratPharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the ratAge-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifosMonte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model.Comparative pharmacokinetics of the organophosphorus insecticide chlorpyrifos and its major metabolites diethylphosphate, diethylthiophosphate and 3,5,6-trichloro-2-pyridinol in the ratAn age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling ratA physiologically based pharmacokinetic model of organophosphate dermal absorptionThe impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic modelPharmacokinetics and metabolism of a single subneurotoxic oral dose of tri-o-cresyl phosphate in hensPharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol (TCPy) in rat salivaComparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult ratPharmacokinetics and pharmacodynamics of chlorpyrifos and 3,5,6- trichloro-2-pyridinol in rat saliva after chlorpyrifos administration24-hour human urine and serum profiles of bisphenol A following ingestion in soup: individual pharmacokinetic data and emographicsDevelopment of a physiologically based pharmacokinetic model for methyl ethyl ketone in F344 ratsEvaluation of the dermal absorption of aqueous toluene in F344 rats using real-time breath analysis and physiologically based pharmacokinetic modelingBayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in ratsThe effect of route, vehicle, and divided doses on the pharmacokinetics of chlorpyrifos and its metabolite trichloropyridinol in neonatal Sprague-Dawley ratsEvaluation of stable isotope-labeled probes in the study of solvent pharmacokinetics in human subjectsThe role of pharmacokinetics and metabolism in species sensitivity to neurotoxic agents
P921
description
Branch of pharmacology dedicat ...... inistered to a living organism
@en
Fachgebiet der Pharmazie
@de
Medikamentuek organismoaren ba ...... aizketa eta abarren) azterketa
@eu
a dinâmica da absorção, distribuição, metabolismo e eliminação dos fármacos
@pt
branca della farmacologia che ...... tti dell'organismo sul farmaco
@it
rama de la farmacología que es ...... és de su paso por el organismo
@es
stof wat levens gevaarlijk is
@nl
ঔষধবিজ্ঞানের শাখা যেখানে জীবদে ...... ঔষধের) পরিণতি অধ্যয়ন করা হয়
@bn
name
Dược động học
@vi
Farmacocinetică
@ro
Farmacocinética
@ast
Farmacocinética
@gl
Farmacocinética
@pt-br
Farmacoqinetega
@lmo
Farmakokineetika
@et
Farmakokinetiikka
@fi
Farmakokinetik
@da
Farmakokinetik
@tr
type
label
Dược động học
@vi
Farmacocinetică
@ro
Farmacocinética
@ast
Farmacocinética
@gl
Farmacocinética
@pt-br
Farmacoqinetega
@lmo
Farmakokineetika
@et
Farmakokinetiikka
@fi
Farmakokinetik
@da
Farmakokinetik
@tr
altLabel
ADME
@de
Absorption Distribution Metabolism Excretion
@de
Farmokokinetik
@tr
LADME
@de
Liberation Absorption Distribution Metabolism Excretion
@de
Toxikokinetik
@de
distribuzione farmacocinetica
@it
farmacocinetica
@es
farmacocinetico
@es
farmacocinético
@es
prefLabel
Dược động học
@vi
Farmacocinetică
@ro
Farmacocinética
@ast
Farmacocinética
@gl
Farmacocinética
@pt-br
Farmacoqinetega
@lmo
Farmakokineetika
@et
Farmakokinetiikka
@fi
Farmakokinetik
@da
Farmakokinetik
@tr
P244
P349
P486
P6366
P646
P1051
P244
sh85100597
P31
P3219
pharmacocinetique
P3417
Pharmacokinetics
P349
P361
P373
Pharmacokinetics
P3827
pharmacokinetics
P4732
P4746
P486
P5082
farmakokinetikk